Newer agents are reenergizing the treatment of hyperkalemia, a serious condition characterized by elevated serum potassium levels in patients with cardiovascular, renal and metabolic diseases, several experts noted.
This improvement in hyperkalemia management has yielded another key benefit: It has allowed the increased use of drugs for heart failure, such as renin–angiotensin–aldosterone system inhibitors (RAASis), which often have been avoided due to their tendency to